Novartis Bets $2 Billion To Deepen Allergy Drug Pipeline

On Friday, Novartis AG (NYSE:NVS) agreed to acquire Excellergy Inc., a private biotech company developing next-generation anti-IgE therapies for IgE-driven diseases. Novartis Expands Allergy Portfolio IgE-driven (IgE-mediated) diseases are type I hypersensitivity reactions where immunoglobulin E antibodies trigger mast cells and basophils, causing rapid allergic reactions or chronic inflammation. The proposed acquisition adds Exl-111, a half-life extended, high-affinity anti-IgE antibody, in Phase 1 trial. Transaction Details And Strategic Rationale Under the terms of the agreement, Novartis will pay up to $2 billion in upfront and milestone payments to acquire Excellergy. The transaction is expected to close in the second half of 2026. The acquisition builds on deep Novartis expertise in IgE biology and a long-standing presence in allergic disease. Exl-111 Mechanism And Early Data Exl-111 is designed as a next-generation extension of validated biology established by anti-IgE therapy, with the potential to complement Novartis existing allergy portfolio. IgE is a central driver of multiple allergic diseases. Unlike conventional anti-IgE approaches, Exl-111 dissociates receptor-bound IgE and has the potential to drive faster and deeper Fc epsilon RI alpha (FcεRIα) downregulation. Preclinical studies and early human pharmacokinetic data from ongoing Phase 1 evaluation support a differentiated profile, with evidence of sustained exposure consistent with its half‑life‑extended design. Novartis Targets Next-Generation Breast Cancer Therapy Last week, Novartis agreed to acquire a next-generation PI3Kα inhibitor program from Synnovation Therapeutics. The deal aimed to strengthen its breast cancer pipeline with a more targeted and potentially better-tolerated treatment approach. The acquisition supports Novartis' broader oncology strategy to develop precision medicines that can be combined with existing treatments, including CDK inhibitors and endocrine therapies, to improve patient outcomes. Deal Structure and Timeline Under the agreement, Novartis will pay $2 billion upfront and up to $1 billion in milestone payments to Synnovation Therapeutics. The transaction includes the acquisition of Pikavation Therapeutics, a subsidiary holding the PI3Kα inhibitor portfolio, including SNV4818. The deal is expected to close in the first half of 2026. NVS Stock Price Activity: Novartis shares were down 0.05% at $149.63 at the time of publication on Friday, according to Benzinga Pro data. Image via Shutterstock